Merck + Co., Inc.

Celgene Corporation

Shaei Y Huang

George W Muller

Hon-Wah Man

Mark E Fraley

Yuan Cheng

Cheng Wang

Alan D Adams

Kenneth L Arrington

Vadim Y Dudkin

Bruno Tse

A Brian Jones

Edward J Brnardic

Clare E Gutteridge

Ahren I Green

The instant invention provides for compounds which comprise substituted triazoloquinazolinones that inhibit CHK1 activity. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting CHK1 activity by administering the compound to a patient in need of treatment of cancer.

Inhibitors of checkpoint kinases

Imido and amido substituted acylhydroxamidic acids which reduce the levels of TNF&#x3b1; and inhibit phosphodiesterase in a mammal. A typical embodiment is (3-(1,3-dioxoisoindolin-2-yl)-3-(3-ethoxy-4-methoxyphenyl)propandylamino)propanoate.

Substituted acylhydroxamic acids and method of reducing TNF&#x3b1;levels

The present invention relates to novel LXR ligands of Formula I and the pharmaceutically acceptable salts, esters and tautomers thereof, which are useful in the treatment of dyslipidemic conditions, particularly depressed levels of HDL cholesterol. 

Therapeutic compounds for treating dyslipidemic conditions

Imido and amido substituted acylhydroxamic acids which reduce the levels of TNF&agr; and inhibit phosphodiesterase in a mammal. A typical embodiment is (3-(1,3-dioxoisoindolin-2-yl)-3-(3-ethoxy-4-methoxyphenyl)propanoylamino)propanoate.

Substituted acylhydroxamic acids and method of reducing TNF&agr; levels

Growing community of inventors

Jeffersonville, PA, United States of America

Shaei Y Huang